<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="17382">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02880605</url>
  </required_header>
  <id_info>
    <org_study_id>2016-1-4031</org_study_id>
    <nct_id>NCT02880605</nct_id>
  </id_info>
  <brief_title>Validation of Chinese Version Appropriate Use Criteria for Coronary Revascularization</brief_title>
  <official_title>Validation of Chinese Version Appropriate Use Criteria for Coronary Revascularization</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>China National Center for Cardiovascular Diseases</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>China National Center for Cardiovascular Diseases</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Coronary revascularization (CR) is increasing rapidly in China and varies significantly in
      proportion ( PCI:CABG=15:1). Few studies assess the appropriateness of CR in China.
      Recently, National Center for Cardiovascular Disease organized experts to release Chinese
      version appropriate use criteria(C-AUC) for coronary revascularization by RAND method aimed
      at regulating indications of CR. The criteria is considered to contribute to clinical
      practices, quality assessment and health insurance policy, however, the validation of C-AUC
      is unknown.

      Thus the investigators study aims at assessing the validation of Chinese AUC by multi-center
      prospective registry. The investigators will recruit 4000 patients undergoing elective
      coronary angiography with positive outcome consecutively and collect baseline information.
      Sequently, one-year follow up will be done to collect the prognose, including death,
      rehospitalization, medicine, medical compliance and life quality etc. One hand, the
      investigators will compare the outcomes between different therapies in the same indications
      according to C-AUC to evaluate the validation of C-AUC. On the other hand, the investigators
      will evaluate the rationality of CAD therapy in Beijing by C-AUC.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2016</start_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Year</target_duration>
  <primary_outcome>
    <measure>Major adverse cardiac and cerebrovascular events (MACCE)</measure>
    <time_frame>1 year</time_frame>
    <description>death, nonfatal myocardial infarction, cerebrovascular event, repeat revascularization</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>death</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>nonfatal myocardial infarction</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cerebrovascular event</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>repeat revascularization</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cost for hospitalization</measure>
    <time_frame>1 year</time_frame>
    <description>Total cost of hospitalization and rehospitalization for cardiac disease in follow-up time</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">4000</enrollment>
  <condition>Appropriate Use Criteria</condition>
  <condition>Coronary Revascularization</condition>
  <arm_group>
    <arm_group_label>appropriate in appropriate indications</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>inappropriate in appropriate indications</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>appropriate in inappropriate indications</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>inappropriate in inappropriate indications</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients undergo elective coronary angiography in department of cardiology in period of
        study.

        Patients are written informed consent.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Undergo elective coronary angiography in department of cardiology in period of study

          -  Written informed consent

        Exclusion Criteria:

          -  Age â‰¤18 years of age

          -  Illiteracy, vision/audition disorder, cognitive disorder etc
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Zhe Zheng, Phd</last_name>
    <phone>13910698957</phone>
    <email>zhengzhe@fuwai.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fuwai Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhe Zheng, MD,PhD</last_name>
      <phone>13910698957</phone>
      <email>zhengzhe@fuwai.com</email>
    </contact>
    <investigator>
      <last_name>Hongbin Yan, MD,PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <lastchanged_date>August 23, 2016</lastchanged_date>
  <firstreceived_date>August 16, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
